| Title |
Choosing the right medication for the treatment of alcoholism
|
|---|---|
| Published in |
Current Psychiatry Reports, October 2006
|
| DOI | 10.1007/s11920-006-0040-0 |
| Pubmed ID | |
| Authors |
Helen M. Pettinati, Amanda R. Rabinowitz |
| Abstract |
In the past decade, scientists have made important progress toward understanding the neurobiology underlying an alcohol disorder. This knowledge has led to the development of promising pharmacotherapies that target the neural pathways involved in the brain's reward center in such a way that the usual treatment response (via counseling) is substantially improved upon. There are now four US Food and Drug Administration (FDA)-approved pharmacotherapies for the treatment of alcohol dependence: disulfiram (Antabuse; Odyssey Pharmaceuticals, East Hanover, NJ), oral naltrexone (ReVia; Barr Pharmaceuticals, Inc., Pomona, NY), acamprosate (Campral; Forest Laboratories, Inc., New York, NY), and, as of April 2006, an extended-release (30-day) injectable suspension formulation of naltrexone (Vivitrol; Alkermes, Inc., Cambridge, MA). Other types of medications (eg, topiramate and quetiapine) are currently under investigation for the treatment of alcohol dependence. Research also has provided insights into best practices for prescribing the available medications. This report reviews the latest innovations in pharmacotherapy for the treatment of alcohol dependence, focusing on FDA-approved medications presently available to the treatment community. |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 3% |
| France | 1 | 3% |
| Unknown | 34 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 25% |
| Professor > Associate Professor | 5 | 14% |
| Other | 3 | 8% |
| Student > Bachelor | 2 | 6% |
| Professor | 2 | 6% |
| Other | 8 | 22% |
| Unknown | 7 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 39% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
| Psychology | 3 | 8% |
| Agricultural and Biological Sciences | 2 | 6% |
| Chemistry | 2 | 6% |
| Other | 4 | 11% |
| Unknown | 8 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 February 2015.
All research outputs
#8,517,130
of 25,392,205 outputs
Outputs from Current Psychiatry Reports
#706
of 1,280 outputs
Outputs of similar age
#30,029
of 86,705 outputs
Outputs of similar age from Current Psychiatry Reports
#5
of 9 outputs
Altmetric has tracked 25,392,205 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,280 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.1. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 86,705 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.